Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of TAK-994 in Narcolepsy Type 1 Extension Study
NCT04820842Phase 2Terminated
- Sponsor
- Takeda
- Start
- Apr 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 2 trial of firazorexton in narcolepsy type 1 (NT1), sponsored by Takeda. Started Apr 2021; status: terminated.
02
Drugs
firazorexton
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT04820842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04820842.